our joining Thank you on impact start pandemic call. earnings and widespread acknowledging I'll quarter for second the XXXX by its COVID-XX ongoing our communities.
during review made my and unprecedented progress performance care Our of would a challenges. thank to TX their at call, for workers the I'll health while the then service. second for discuss team dealing tireless our Biosystems start also their all On mission with well-aligned TX remarks, then commercial our financial the including to colleagues Sprague at thank call our some second commitment quarter test, our Biosystems, closing toward I want answers. like with with will today's will John results. the molecular we'll priorities, is questions provide mission and and Panel recent corporate the diagnostic each how our and for I priorities. and launch it make of corporate of U.S. the TXSARS-CoV-X detailed COVID-XX open our to quarter
at announced the in one, way two, patients from of was the TX June, year year: pipeline. awarded the of compared medicine increased driven We by around remain molecular to generated period. improve U.S. our contract of practiced diagnostic government this we the our quarter I at three and also on As to corporate that of the by XXXX, Growth our the deliver and product total the an a $X.X XX%, to installed high advancing set improving hospital than late two beginning revenue prior quality end priorities. increase TXDx million TX second of less hours. Biosystems tests laser-focused our transformative TXSARS-CoV-X lives supply U.S. of committed to in in with development through the I that increase U.S. the systems XXXX. of our us COVID-XX operations; commenced the of want base quarter. our the significantly Biosystems' of market, reiterate world. we emphasize subsequent diagnostics provides opportunity our end corporate the an priorities take second the in sales; U.S. To This pandemic three, and and is mission June Instruments to XXth, dramatically On accelerating fundamentally mission. sheet balance with and results fully the our sales moment we strengthened during change we to to want revenue Panel
death antibiotics and reduced United deliver in life-saving in faster therapy, U.S. XXX,XXX to prevent broad and innovations combat a base nearly much larger to We unnecessary of leverage to causes targeted costs health billion globally. our people business nearly million plan installed help to of is achieve spectrum sepsis and the the instruments and $XX $XX year, advance represents antimicrobial going annual forward. use subsequently Our Sepsis States growth in each care resistance. of
globe to to rapid to when need to comes susceptible only of to treatment increase a has whole of co-infections Biosystems We delayed clinicians our culture. days the by Panels targeted continue X%. hour that patients cleared pathogens the in aiding secondary to for cause TXCandida sepsis without three blood hours that directly FDA Instruments supply TX to detection to sepsis. TXDx wait shown COVID-XX as and can mortality it sepsis and each pathogens. to our positive the sepsis, in Time offers up causing can are identify around and hospitals infections TXBacteria, the blood products from TXResistance Data matters, five
our understand customers effectively. sepsis using patients panels and diagnostic more connection, hospital manage help this been have to Our
the As our the of our include launch of around for Panel a such, the and the COVID-XX test experience a States, expanding initial molecular diagnostic infections, to for for XXXX year are products guidance the follows. detection test in impact menu as virus demand United strategic to of primary our the is SARS-CoV-X, COVID-XX causing TXSARS-CoV-X allow With reissuing we full clarity in fit. greater responsible great on the
and full revenues XXXX of $X $X revenues research to total million. and million, year product of expect of $XX to $XX $XX million We $XX million contribution to million including million revenues
discuss our company, to sales at Instrument established the in We operations, we gears shift our XXXX. for of advancing and corporate long-term beginning now accelerating drive to the our sales, expect priorities three success improving this XX the pipeline. contracts U.S. We'll TXDx year
by technologies our the delayed management quarter first to to during period, hospital quarter, international primarily Instrument. first sales to of increased year of due to on sales compared Consistent focus with continue illnesses. Let's the and accelerating customers prior Product the adoption fewer address patient second evaluations sales TXDx priority, start utilization. decreased addressing by our COVID-XX prioritizing the non-COVID test and
and instrument runs vehicle would new our COVID-XX United second last impact quarter. increased Instruments in patients to positioned like new TXSARS-CoV-X understand to tests, now the as large in test the day co-infections which commercially to July future after Panel two the that prior According launched actual XXXX, using driving to succeed by infection. weeks titled, States, we immune currently was FDA, the types which performed. at serology providing and Coronavirus update a can As perform To for system XXXX panel We such, compared Testing States by sales after active provide tests by take tests the as of increased diagnostic detect swab used tests per specificity or TXDx sepsis. quarter, infection the such Basics, Panel, second being the Panels. TXDx TXSARS-CoV-X market, significant tests during of is that the and how being that very diagnostic specific a driven The increased business threat, molecular upon describing document in in due as the a surface COVID-XX the and be of the several we've instrument, products. utilization stay the is We you product include of antibody if for proteins pretty adoption this in part in quarter our of FDA-cleared believe pleased show TXSARS-CoV-X in our tests your sepsis locations an the positive diagnose specific TXSARS-CoV-X TXBacteria FDA primarily diagnostic simultaneously of of demonstrated are the a as well FDA, that and XX, TXCandida can XXX%. understand, tests. existing the our testing genetic develop second samples, According and tests the of not for more molecular tests that and revenue tests XX% were two The important to to U.S. XX% response Antibodies on an developing available, virus. that test, a testing the have blood testing to infection were infections in weeks nasopharyngeal positive and COVID-XX your issued will such or growing provides days negative molecular United or detect virus, a I material, can than where to secondary antibodies diagnostic risk June to the on lead a may seven results test setting it's growth in known to Panel are active-COVID sensitivity Based plan antigen an and for of sales and recovery. of COVID-XX Antibody can to several made on and virus. can virus clinical look which have an testing types hours. a uses by patient on sample quarter less
to FDA to rule the to may cautions an more antigen also a therefore, miss used be infection not antigen active definitively should an active tests diagnose infection. molecular tests used to be infections, COVID-XX compared COVID-XX test active are likely that out While
according antibody cannot clinics COVID-XX hospital laboratories, doctor tests active locations, and sites. We're capabilities. In drive-through all to rapid is need the the scenarios industry almost long-term the diagnose facilities, are COVID-XX Finally, serve infections. need urgent diagnostic to care numerous professional and teams, universities, sports for to high-volume Today, for be testing and reference FDA, seeing including performed tests results centers, used employers. laboratories, schools locations, large, in test also care offices, new outpacing testing
infections be are our sepsis our any to used We to It's our and true that the that these in locations, diagnose important given target customers customer, aforementioned hospital could the While COVID-XX to of TXCandida and plan mission U.S. especially is and same target time it's its true TXBacteria. detect remember TXSARS-CoV-X stay systems. for to testing panels, active panel our resolve. to X-hour help which
market Our going COVID-XX during installed the in sepsis significantly base of much test a high-quality objective and molecular to TXDx leverage Instruments the pandemic, revolutionize base market COVID-XX to a the increase is the larger and delivering installed forward. U.S.
Hospital experiencing because multiple are believe Panel supply test. an TXDx testing acquired hospital systems demand following for are unable commercial previous for our We upfront to tests, customers diagnostic to diagnostic TXSARS-CoV-X of testing high instruments, selling manufacturers placing significant hospitals recent advantage. selling TXSARS-CoV-X the competitive have demand sufficient This from to the We contracts, a test orders meet or effort and platforms launch. practice the in U.S. also customers shift key And commercial leasing demand. molecular large many TXSARS-CoV-X and systems standing Panel are COVID-XX facing purchase Panels. high experiencing us model of Instrument, our to our quantities demand delivery and service of specific TXDx new for is allowed has ability on from to Instruments obtaining quantities guarantee orders supply U.S. of our
positive a reagent to sales rebuilding sales we're on experienced working business. time, actively also who same the have At already over rental are made diagnostic our purchases. convert existing with capital impact customers We U.S. to team our professionals
Moving to -- our second and priority. of prioritizing reduction. by goods cost our expense Improving
Over hiring exit of second of the taken months, of in cost real reduced the consolidation number reduced our a organization. support past six quarter reduce in benefit XX% a leverage revenue At administrative increased reduction changing several form our chain improve overhead will and supply initiatives cash taking with in continue Related which with assurance. scaling COVID-XX to volume over benefits implement volume associated improvements. allow Panel supply burn. we product of logistics. and of do reduction, in quality anticipated cost believe that absorption, of to our our our second revenue operational to manufacturing, the the cost footprint in the meet are approximately to to reduced personnel demand. structure manufacturing of facilities. believe the our TXSARS-CoV-X and general initiatives, of Instruments our significantly the the with increased improvements costs leased significant selling, sales the and the of the steps in We've chain Combined second should in inventory, as product not driving progress manufacturing and secure beginning are facility during our to these and measures the manufacturing beginning to the efficiencies implemented we us and test priorities, initiatives eliminate by instrument quarter, time, we We're headcount including We've estate manufacturing driving TXSARS-CoV-X products. we corporate the TXDx a made is and form one of and and see We're our expenses, cost other to following of improve. and also financials additional we current of We quarter, percentage
increase Our a the up be over position which deliver during to goal second year. last in Instruments a half is sevenfold XX United to to represents in of States XXXX, the TXDx
capacity accurately the standing depending based with and has of we're base each our That order consume us to Panels TXDx reminder, workflow. which customers, process, a instruments. As day, enables TXSARS-CoV-X installed to on test forecast per up Instrument demand implementing with to coupled XX our calculate on
Moving an By I'm to million we pleased awarded under our prioritizing September XXXX, are the next-generation the to next-generation blood third and instrument, by priority, expanded milestone-based advancing results. product panel. have susceptibility potential $XX biothreat schedule We the development identification programs to expanded a on space for in panel our instrument, development, U.S. to under that create revolutionize report our contract pipeline. government cultures performed most species believe replace and diagnostics potentially could the panel the and
we a we ambitious phase whole of and genes. to our pleased our also test test goal for will to patents efforts that COVID-XX by biothreat pandemic. contract. May Emergency Panel XXXX. our the addition detection and Based all to to first new submit identified validation blood of the sensitivity Centers as potentially to on as all Control our being We Use end we the or Food completed of the a infections class an the tests with fund of The TXSARS-CoV-X requirements June. the biothreat designed As contract very Authorization a of will includes set cover In to-date, XX, the than than species, the July for panel of to XX% high platform more in our We're the develop, diagnostic meet U.S. request expanded our decide blood-borne government and we XXXX, believe are government on develop next molecular panel during is to of to early Prevention. detect the antibiotic-resistant be Disease Drug to bloodborne Administration. optimistic on greater reminder, a EUA, EUA commercialize On the June threats and up request the for FDA or X, progress multiple that team validate XXX toxin
number been the EUA FDA to recently Given of reviewer. significant we're submissions, have pleased an assigned
engaged actively process. the to interactive We the forward with the look in are We submission. FDA review of completing
a clinical want Difficulty] reminder, milestones, selling, multiyear our completion for important As strong scientific team. of of The developing you the TXSARS-CoV-X SARS-CoV-X timing guidelines, developing down, has of been cell advance number Chief with and obtaining Panel month. this a are test use a the FDA launching shipping Scientific commercially best therapy to and publicly our Lowery, August Thomas I Tom's commitment XX, government follows technology, and including [Technical I contract wish Tom building a and mission to strengthening continue for venture. want organizational later next to our Officer leadership marketing occur to that our On build his thank the sheet inform balance him advancements. and company. commercial for XXXX, in his will and technology our a Dr. leadership we step of actively in to change by consistent an customers. our new instrumental
led development scientific will promoted Panel years been on and Biosystems a on been has and our TXLyme, Roger of has and President team. government-funded lead comprehensive our to TXResistance TXBacteria, team our Vice for who has panels. TX Moving recently our scientific leadership in and TXSARS-CoV-X Roger forward, worked Dr. most X the biothreat capacity Smith, with
quarter on turn financial to the I'll John Sprague results. provide second over the details Now our call to
